Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim

被引：0
|
作者：
H. Xu
Q. Gong
F. D. Vogl
M. Reiner
J. H. Page
机构：
[1] Amgen Inc.,Center for Observational Research
[2] Amgen Inc.,Global Biostatistical Science
[3] Amgen Inc.,Hematology/Oncology
[4] Amgen Inc.,Global Biostatistical Science
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
Bone pain; Chemotherapy; Pegfilgrastim; Risk factors; G-CSF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：723 / 730
页数：7
相关论文
共 50 条
  • [31] Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy
    Eldar-Lissai, Adi
    Cosler, Leon E.
    Culakova, Eva
    Lyman, Gary H.
    VALUE IN HEALTH, 2008, 11 (02) : 172 - 179
  • [32] The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies
    Whitworth, J.
    Matthews, K. S.
    Shipman, K.
    Numnum, T. M.
    Kendrick, J. E.
    Kilgore, L. C.
    Straughn, J. M.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S31 - S31
  • [33] Economic analysis of prophylactic pegfilgrastim in cancer patients receiving chemotherapy.
    Eldar-Lissai, A
    Cosler, LE
    Lyman, GH
    BLOOD, 2004, 104 (11) : 608A - 608A
  • [34] Once per cycle pegfilgrastim compaired to daily filgrastim after myelosuppressive chemotherapy in paediatric cancer patients
    Cacchione, Antonella
    Ferrara, Eva
    Roberti, Micol
    D'Attilia, Francesca
    Schiavo, Elisa
    Cappelli, Carlo
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 512 - 512
  • [35] Fatigue Level and Contributing Factors Among Cancer Patients Receiving Chemotherapy
    Hussein, Dhiaa Alrahman
    Sameen, Faisal Younus
    JOURNAL OF PIONEERING MEDICAL SCIENCES, 2023, 12 (04): : 51 - 55
  • [36] Empiric dose reduction of pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy
    Paba, C.
    Sachdev, J.
    Kronish, L.
    Jahanzeb, M.
    Waheed, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Risk factors for thromboembolic events in testicular cancer patients receiving chemotherapy
    Shim, K.
    Potvin, K. R.
    Mills, K.
    Whiston, F.
    Stitt, L.
    Winquist, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support
    Wolff, AC
    Jones, RJ
    Davidson, NE
    Jeter, SC
    Stearns, V
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2392 - 2394
  • [39] Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy
    Volovat, Constantin
    Gladkov, Oleg A.
    Bondarenko, Igor M.
    Barash, Steve
    Buchner, Anton
    Bias, Peter
    Adar, Liat
    Avisar, Noa
    CLINICAL BREAST CANCER, 2014, 14 (02) : 101 - 108
  • [40] Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas
    Chan, Alexandre
    Lee, Chee Ping
    Chiang, Joen
    Ng, Raymond
    SUPPORTIVE CARE IN CANCER, 2013, 21 (08) : 2137 - 2143
12345